Our news section contains recent news on neuroendocrine tumors, upcoming NANETS events and information, and people in our community. Have a suggestion? Please click here to contact us.

NANETS Announces Symposium Keynote

Drew Pardoll, MD, PhD, of Johns Hopkins Medical Institutions, will be presenting the keynote on 

NANETS2017 Early Bird Registration - Open Now!

The North American Neuroendocrine Tumor Society (NANETS) invites you to attend our 10th Annual Symposium. Join us in Philadelphia, Pennsylvania, USA, on October 19-21, 2017 for the premier gathering of medical professionals involved in the study and treatment of neuroendocrine tumor (NET) disease.

Featured in Pancreas

Featured in the March 2017 issue of Pancreas are the NANETS 2016 symposium 

NANETS2017 Call for Abstracts - Open Now!

The North American Neuroendocrine Tumor Society (NANETS) welcomes abstracts for the 10th annual NANETS Symposium, which will be held in Philadelphia, Pennsylvania, USA, on October 19-21, 2017. The deadline for abstract submissions is Monday, June 26, 2017.

NANETS Transition Update

It has been a little over a month since we established our new headquarters and staff in New York. I'm pleased to report it has been a productive transition which has allowed us to align our organization with many of our strategic goals.

In memoriam Dirk J. Kwekkeboom (1958 - 2017)

Dirk J. KwekkeboomDirk J. Kwekkeboom, MD, widely regarded as one of Europe’s foremost experts on peptide receptor radiotherapy (PRRT), passed away March 8, 2017, at the age of 58. 

NANETS Welcomes New Management Team

In January, NANETS extended its thanks and gratitude to our outgoing executive director. This month, I share the news that NANETS has established a new office headquarters and staff.

FDA approves Xermelo for carcinoid syndrome diarrhea

The U.S. Food and Drug Administration today approved Xermelo (telotristat ethyl) tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone has inadequately controlled. 

Jan 2017 NETwork Connection- Clinical Trials

Clinical Trials In the News:

On January 12, that the New England Journal of Medicine published the results of the NETTER-1 Phase III study evaluating efficacy and safety of Lutathera® (lutetium-177 dotatate), an investigational drug, in patients with advanced, progressive somatostatin receptor-positive midgut neuroendocrine tumors (“NETs”).